Avacta Group widens half-year losses as sales slow

Animal and human healthcare company Avacta Group widened its half-year losses as revenues slowed during the introduction of new Optim analytical devices.

Animal and human healthcare company Avacta Group widened its half-year losses as revenues slowed during the introduction of new Optim analytical devices.

The provider of analytical and diagnostic technologies to the pharmaceutical and animal healthcare sectors, posted an operating loss of £0.97m in the six months to the end of January, up from £0.52m the previous year.

Revenues dropped to £1.15m from £1.72m during the transition from Optim1 to Optim2, an analytical instrument designed to probe multiple protein stability-indicating parameters.

The company has received orders for 10 units since launching the product on February 1st.

During the period, the company invested in training its sales team at ForteBio, the the newly acquired subsidiary of partner Pall Corporation. ForteBio is the key distributor for the US market of the Optim product.

"Revenues fell because Optim sales slowed as we introduced Optim2 and trained up the sales team at ForteBiom," Chief Executive Officer Alastair Smith told Digital Look and Sharecast.

He said it was a transformational period for the company which resulted in a short-term slowdown that will drive performance in the long run.

The company expects to launch its new Affimer reagents next year as development remains in line with management's expectations.

"The antibody replacement technology presents a lot of growth opportunities," he said.

"Over the next half we anticipate further progress across all divisions."

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021
It's not just the UK – we're seeing pandemic housing booms across the globe
Property

It's not just the UK – we're seeing pandemic housing booms across the globe

Soaring house prices aren’t just a UK thing, they’re a worldwide phenomenon. And it’s no coincidence – the underlying cause is much the same. John Ste…
18 Jan 2021